Supplementary Materials and Methods from Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas

Xue-Li Bai,Qi Zhang,Long-Yun Ye,Qi-Da Hu,Qi-Han Fu,Xiao Zhi,Wei Su,Ri-Ga Su,Tao Ma,Wei Chen,Shang-Zhi Xie,Cong-Lin Chen,Ting-Bo Liang

DOI: https://doi.org/10.1158/1535-7163.22501008

2023-01-01

Abstract:PDF - 169K, Supplementary Materials and Methods.

What problem does this paper attempt to address?

Suppression of phenylacetate on hepatic carcinoma line and its mechanism

Zi-hui MENG,Tao JIANG,Hang LI,De-gang JI,Yong-sheng YANG,Xue-wen ZHANG

DOI: https://doi.org/10.13481/j.1671-587x.2009.05.058

2009-01-01

Abstract:Objective: To study the inhibitory effect of phenylacetate (PA) on hepatic carcinoma cells for developing of gene therapy. Methods: SSMC-7721 cells were treated with or without PA (0.25, 0.50, 1.00, 2.00, 4.00 mmol·L -1) for 24, 48 and 72 h, respectively. The cellular proliferation inhibitory rate was evaluated by MTT assay. Flow cytometry was used to estimate the changes of cell cycle. The morphous of tumor cells suppressed by PA was observed with electronic microscope. Finally, the activity of Caspase-3 protein to estimate the way of apoptosis of SSMC-7721 cells under the control of PA was determined. Results: The growth of SSMC-7721 cells were inhibited by 0.25-4.00 mmol·L-1 PA for 24-72 h. With the increase of concentration of PA, the proliferation inhibitory rate were 7.2%-73.1 % at 24 h, 9.1%-87.5% at 48 h, 15.8%-91.9% at 72 h. With the prolongation of treating time and the increasing of PA concentration, the inhibitory rate was increased. 2.00 mmol·L-1 was the best concentration for the experiment. The cell cycle was arrested at G0/ G1 and G2/M phase. Some characteristic changes of apoptosis were observed by electronic microscope, the activity of Caspase-3 protein in SSMC-7721 mediated by PA was increased. Conclusion: PA could effectively inhibit SSMC-7721 cell proliferation and induce the apoptosis. Caspase-3 protein at least partly participate in the mechanism.
Supplementary Tables 1 and 2 and Supplementary Figures 1 Through 7 from Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas

Xiangzhi Bai,Qi Zhang,Long‐Yun Ye,Qi-Da Hu,Qihan Fu,Xiao Zhi,Wei Su,Ri-Ga Su,Tao Ma,Wei Chen,Shangzhi Xie,Cong-Lin Chen,Tingbo Liang

DOI: https://doi.org/10.1158/1535-7163.22501005.v1

2023-01-01

Abstract:PDF - 627K, Supplementary Table S1 IC50 values and statistical analyses of doxorubicin and doxorubicin plus LB-100 treatments in HCC cell lines; Supplementary Table S2: IC50 values and statistical analyses of cisplatin and cisplatin plus LB-100 treatments in HCC cell lines; Supplementary Figure S1: Toxicity of LB-100 in different cell lines; Supplementary Figure S2. Clonogenic assays of LB1 chemosensization; Supplementary Figure S3: PP2A_C overexpression attenuated LB-100 chemosensitization in vitro and in vivo; Supplementary Figure S4: Percentage of cells with abnormal nuclei; Supplementary Figure S5: PP2A activity is associated with VEGF secretion; Supplementary Figure S6: Pictures of HUVECs monolayers before and after doxorubicin treatment as indicated in Fig. 6A; Supplementary Figure S7: LB-100 facilitated early entry of doxorubicin into tumor cells.
Supplementary Materials and Methods from Serglycin is a Theranostic Target in Nasopharyngeal Carcinoma That Promotes Metastasis

Xin-Jian Li,Choon Kiat Ong,Yun Cao,Yan-Qun Xiang,Jian-Yong Shao,Aikseng Ooi,Li-Xia Peng,Wen-Hua Lu,Zhongfa Zhang,David Petillo,Li Qin,Ying-Na Bao,Fang-Jing Zheng,Claramae Shulyn Chia,N. Gopalakrishna Iyer,Tie-Bang Kang,Yi-Xin Zeng,Khee Chee Soo,Jeffrey M. Trent,Bin Tean Teh,Chao-Nan Qian

DOI: https://doi.org/10.1158/0008-5472.22390673.v1

2023-01-01

Abstract:Supplementary Materials and Methods from Serglycin Is a Theranostic Target in Nasopharyngeal Carcinoma that Promotes Metastasis
Supplementary Methods from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Mengyu Xie,Hong Zheng,Ranjna Madan-Lala,Wenjie Dai,Nicholas T. Gimbrone,Zhihua Chen,Fumi Kinose,Sarah A. Blackstone,Keiran S.M. Smalley,W. Douglas Cress,Eric B. Haura,Uwe Rix,Amer A. Beg

DOI: https://doi.org/10.1158/0008-5472.22422753

2023-01-01

Abstract:Supplementary Methods for Xie et al, MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer
Supplemental Materials and Methods and Supplemental Figure Legends from Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells

Bryan Wei Chen,Wei Chen,Hui Liang,Hao Liu,Chao Liang,Xiao Zhi,Li-qiang Hu,Xia-Zhen Yu,Tao Wei,Tao Ma,Fei Xue,Lei Zheng,Bin Zhao,Xin-Hua Feng,Xue-li Bai,Ting-bo Liang

DOI: https://doi.org/10.1158/1535-7163.22502419

2023-01-01

Abstract:Supplemental Materials and Methods and Supplemental Figure Legends
Supplementary Materials and Methods from An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis

Xiumei Huang,Ying Dong,Erik A. Bey,Jessica A. Kilgore,Joseph S. Bair,Long-Shan Li,Malina Patel,Elizabeth I. Parkinson,Yiguang Wang,Noelle S. Williams,Jinming Gao,Paul J. Hergenrother,David A. Boothman

DOI: https://doi.org/10.1158/0008-5472.22391745

2023-01-01

Abstract:PDF file - 133K, A detailed description of all Materials and Methods used in the Supplemental Figures and Tables.
Supplementary Materials and Methods from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Xinyao Qiu,Shuai Yang,Shan Wang,Jianmin Wu,Bo Zheng,Kaiting Wang,Siyun Shen,Seogsong Jeong,Zhixuan Li,Yanjing Zhu,Tong Wu,Xuan Wu,Rui Wu,Weiwei Liu,Hong-Yang Wang,Lei Chen

DOI: https://doi.org/10.1158/0008-5472.22429342

2023-01-01

Abstract:Supplementary Materials and Methods
Supplementary materials and methods from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Jialei Weng,Zheng Wang,Zhiqiu Hu,Wenxin Xu,Jia-Lei Sun,Fu Wang,Qiang Zhou,Shaoqing Liu,Min Xu,Minghao Xu,Dongmei Gao,Ying-Hao Shen,Yong Yi,Yi Shi,Qiongzhu Dong,Chenhao Zhou,Ning Ren

DOI: https://doi.org/10.1158/0008-5472.25964576.v1

2024-01-01

Abstract:Supplementary materials and methods
Supplementary Data from HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression

Yufei Wang,Man Zhao,Lina Zhao,Yu Geng,Guanghao Li,Lin Chen,Jingxuan Yu,Hongfeng Yuan,Huihui Zhang,Haolin Yun,Ying Yuan,Guowen Wang,Jinyan Feng,Liang Xu,Shuai Wang,Chunyu Hou,Guang Yang,Ningning Zhang,Wei Lu,Xiaodong Zhang

DOI: https://doi.org/10.1158/0008-5472.22433561.v1

2023-01-01

Abstract:Supplementary materials and methods, Supplementary figures, Supplementary figure legends, Supplementary tables
Supplementary Tables 1-2 from Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation

Zhen-Bin Ding,Bo Hui,Ying-Hong Shi,Jian Zhou,Yuan-Fei Peng,Cheng-Yu Gu,Hua Yang,Guo-Ming Shi,Ai-Wu Ke,Xiao-Ying Wang,Kang Song,Zhi Dai,Ying-Hao Shen,Jia Fan

DOI: https://doi.org/10.1158/1078-0432.22443165.v1

2023-01-01

Abstract:PDF file - 5150K
Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Lixing Zhang,Hefen Sun,Fangyu Zhao,Peixiang Lu,Ge Chen,Hong Li,Helei Hou,Mingxia Yan,Taoyang Chen,Guoping Jiang,Haiyang Xie,Ying Cui,Xiaowu Huang,Jia Fan,Ming Yao,Jinjun Li

DOI: https://doi.org/10.1158/0008-5472.22395141

2023-01-01

Abstract:PDF file - 47K, Sequences of primers used in this study
Supplementary Materials and Methods from Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer

Hong Liu,Yiyang Xu,Jingyi Xiang,Li Long,Shon Green,Zhiyuan Yang,Bryan Zimdahl,Jingwei Lu,Neal Cheng,Lucas H. Horan,Bin Liu,Su Yan,Pei Wang,Juan Diaz,Lu Jin,Yoko Nakano,Javier F. Morales,Pengbo Zhang,Lian-xing Liu,Binnaz K. Staley,Saul J. Priceman,Christine E. Brown,Stephen J. Forman,Vivien W. Chan,Cheng Liu

DOI: https://doi.org/10.1158/1078-0432.22467768

2023-01-01

Abstract:Supplementary Materials and Methods
Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395239.v1

2023-01-01

Abstract:Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Supplementary Figure 5 from Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair

Dongping Wei,Leslie A. Parsels,David Karnak,Mary A. Davis,Joshua D. Parsels,Amanda C. Marsh,Lili Zhao,Jonathan Maybaum,Theodore S. Lawrence,Yi Sun,Meredith A. Morgan

DOI: https://doi.org/10.1158/1078-0432.22450100

2023-01-01

Abstract:PDF file - 52K, LB100 causes an increase in pHistone H3 positive cells.
Supplementary Material and Methods from New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity

Hangxiang Wang,Zhongjie Lu,Lijiang Wang,Tingting Guo,Jiaping Wu,Jianqin Wan,Liqian Zhou,Hui Li,Zhen Li,Donghai Jiang,Penghong Song,Haiyang Xie,Lin Zhou,Xiao Xu,Shusen Zheng

DOI: https://doi.org/10.1158/0008-5472.22416861

2023-01-01

Abstract:Description of synthesis of compounds, additional experiments and procedures, and Table S1
Supplementary Materials and Methods, Table 1, Figures 1 - 6 from SCP Phosphatases Suppress Renal Cell Carcinoma by Stabilizing PML and Inhibiting mTOR/HIF Signaling

Yu-Ching Lin,Li-Ting Lu,Hsin-Yi Chen,Xueyan Duan,Xia Lin,Xin-Hua Feng,Ming-Jer Tang,Ruey-Hwa Chen

DOI: https://doi.org/10.1158/0008-5472.22403930.v1

2023-01-01

Abstract:Supplementary Materials and Methods: Description of additional methods used in this study. Supplementary References: List of references cited in Supplementary Materials and Methods. Supplementary Table 1: SCP1 expression in various tumors. Supplementary Figure 1. Screen for PMLS518 phosphatases. Supplementary Figure 2. The specificity of SCP1 antibody. Supplementary Figure 3. Representative IHC staining results for PML, pS518PML, SCP1, SCP3, and KLHL20. Supplementary Figure 4. The effects of combined inhibition of mTOR and PML degradation pathway in suppressing ccRCC. Supplementary Figure 5. The effects of combined treatment on tumor angiogenesis and mice body weight. Supplementary Figure 6. The effect of SCP1 on PML in PC-3 cells.
Supplementary Table 1 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Lixing Zhang,Hefen Sun,Fangyu Zhao,Ping Lu,Chao Ge,Hong Li,Helei Hou,Mingxia Yan,Taoyang Chen,Guoping Jiang,Haiyang Xie,Ying Cui,Xiaowu Huang,Jia Fan,Ming Yao,Jinjun Li

DOI: https://doi.org/10.1158/0008-5472.22395144.v1

2023-01-01

Abstract:PDF file - 82K, Antibodies used in this study
Supplementary Materials SM1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, is Highly Active Against Triple-Negative Breast Cancer

Peng,Xiaoyan Qiang,Guoyu Li,Lin Li,Shumao Ni,Qi Yu,Laura Sourd,Elisabetta Marangoni,Chao Hu,Dong Wang,Di Wu,Frank Wu

DOI: https://doi.org/10.1158/1535-7163.22523257.v1

2023-01-01

Abstract:This includes the supplementary methods and supplementary table captions.
Supplemental Materials and Methods from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies

Yu-Wei Li,Lei-Jie Dai,Xiang-Rong Wu,Shen Zhao,Yu-Zheng Xu,Xi Jin,Yi Xiao,Ying Wang,Cai-Jin Lin,Yi-Fan Zhou,Tong Fu,Wen-Tao Yang,Ming Li,Hong Lv,Siyuan Chen,Anita Grigoriadis,Yi-Zhou Jiang,Ding Ma,Zhi-Ming Shao

DOI: https://doi.org/10.1158/0008-5472.27603358

2024-01-01

Abstract:Supplemental Materials and Methods
Supplementary Figure 2 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Sharad Sharma,Junying Zeng,Chun-Mei Zhuang,Yong‐Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22497784.v1

2023-01-01

Abstract:PDF file - 68K, Figure S2: Effect of BMS-777607 on breast cancer cell growth and apoptotic death.

Supplementary Materials and Methods from Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas

Suppression of phenylacetate on hepatic carcinoma line and its mechanism

Supplementary Tables 1 and 2 and Supplementary Figures 1 Through 7 from Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas

Supplementary Materials and Methods from Serglycin is a Theranostic Target in Nasopharyngeal Carcinoma That Promotes Metastasis

Supplementary Methods from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Supplemental Materials and Methods and Supplemental Figure Legends from Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells

Supplementary Materials and Methods from An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis

Supplementary Materials and Methods from M<sup>6</sup>A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Supplementary materials and methods from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Supplementary Data from HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression

Supplementary Tables 1-2 from Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Materials and Methods from Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer

Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Figure 5 from Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair

Supplementary Material and Methods from New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity

Supplementary Materials and Methods, Table 1, Figures 1 - 6 from SCP Phosphatases Suppress Renal Cell Carcinoma by Stabilizing PML and Inhibiting mTOR/HIF Signaling

Supplementary Table 1 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Materials SM1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, is Highly Active Against Triple-Negative Breast Cancer

Supplemental Materials and Methods from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies

Supplementary Figure 2 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Materials and Methods from Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas

Suppression of phenylacetate on hepatic carcinoma line and its mechanism

Supplementary Tables 1 and 2 and Supplementary Figures 1 Through 7 from Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas

Supplementary Materials and Methods from Serglycin is a Theranostic Target in Nasopharyngeal Carcinoma That Promotes Metastasis

Supplementary Methods from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Supplemental Materials and Methods and Supplemental Figure Legends from Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells

Supplementary Materials and Methods from An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis

Supplementary Materials and Methods from M&lt;sup&gt;6&lt;/sup&gt;A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Supplementary materials and methods from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Supplementary Data from HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression

Supplementary Tables 1-2 from Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133&lt;sup&gt;+&lt;/sup&gt; Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Materials and Methods from Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer

Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Figure 5 from Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair

Supplementary Material and Methods from New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity

Supplementary Materials and Methods, Table 1, Figures 1 - 6 from SCP Phosphatases Suppress Renal Cell Carcinoma by Stabilizing PML and Inhibiting mTOR/HIF Signaling

Supplementary Table 1 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Materials SM1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, is Highly Active Against Triple-Negative Breast Cancer

Supplemental Materials and Methods from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies

Supplementary Figure 2 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Materials and Methods from M<sup>6</sup>A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma